Why is Biofil Chemicals falling/rising?

As of 02-Sep, Biofil Chemicals & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 43.55, which reflects a decrease of 0.52 or 1.18%. The stock has underperformed its sector today by 1.11%, and while it is higher than its 5-day moving average, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages. The stock's delivery volume has significantly decreased, falling by 96.14% against the 5-day average, indicating a drop in investor participation. Over the past week, the stock has shown a modest gain of 1.28%, but it has underperformed the benchmark over longer periods, with a year-to-date return of -24.19% compared to the Sensex's +3.95%. Positive factors include impressive quarterly results with a 1652.7% growth in PAT and a high EPS, but these are overshadowed by weak long-term fundamentals, including a -25.47% CAGR in operating profits over the last five years and a low return on equity. In the broader market context, Biofil Chemicals has consistently underperformed against the benchmark, with a one-year return of -31.90% compared to the Sensex's -2.77%. This trend of underperformance has been evident over the last three years, where the stock has lagged behind the BSE500 in each annual period. Despite attractive valuations and significant profit growth, the company's weak ability to service its debt and low profitability per unit of shareholders' funds contribute to a negative outlook, leading to a decline in stock price.